Dormancy in solid tumors: Implications for prostate cancer

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 501-509

  Ruppender, Nazanin S ^a   Morrissey, Colm ^a   Lange, Paul H ^a,b   Vessella, Robert L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Disseminated tumor cells; Dormancy; Metastasis; Prostate cancer

Indexed keywords

BETA CATENIN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P16; PROTEIN P21; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; WNT PROTEIN; WNT16B PROTEIN;

ANGIOGENESIS; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER DORMANCY; CANCER RECURRENCE; CELL PROLIFERATION; CIRCULATING TUMOR CELL; DISEASE COURSE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENOTOXICITY; GLEASON SCORE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MICROENVIRONMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR; STRESS; STROMA CELL; TUMOR GROWTH; TUMOR INVASION;

APOPTOSIS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM, RESIDUAL; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84890313588     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9422-z     Document Type: Review

References (72)

1. Amling, C., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J., & Zincke, H. (2000). Long term hazard of progression after radical prostatectomy for clinically localized prostate cancer. Journal of Urology, 164, 101-105.
2. Pound, C., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., & Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association, 281, 1591-1597.
3. Budaus, L., Isbarn, H., Eichelberg, C., Lughezzani, G., Sun, M., Perotte, P., Chun, F. K., Salomon, G., Steuber, T., Kollermann, J., Sauter, G., Ahyai, S. A., Zacharias, M., Fisch, M., Schlomm, T., Haese, A., Heinzer, H., Huland, H., Montorsi, F., Graefen, M., & Karakiewicz, P. I. (2010). Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pahtological stage. Journal of Urology, 184(4), 1341-1346.
4. Ahove, D., Hoffman, K. E., Hu, J. C., Choueiri, T. K., D'Amico, A. V., & Nguyen, P. L. (2010). Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence? Implications for a risk adapted follow-up strategy. Urology, 76(5), 1201-1205.
5. Fidler, I. (1970). Metastasis: quantitative analysis of distribution and fate of tumor emolilabeled with 125 I-5-iodo-2′-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773-782.
6. Langley, R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128(11), 2527-2535.
7. Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., Oommen, N. B., Hawche, G., Jameson, C., Thompson, E., Sipkema, R., Carden, C. P., Parker, C., Dearnaley, D., Kaye, S. B., Cooper, C. S., Molina, A., Cox, M. E., Terstappen, L. W., & deBono, J. S. (2009). Characterization of ERG, AR, and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Research, 69(7), 2912-2918.
8. Bölke, E., Orth, K., Gerber, P. A., Lammering, G., Mota, R., Peiper, M., Matuschek, C., Budach, W., Rusnak, E., Shaikh, S., Dogan, B., Prisack, H. B., & Bojar, H. (2009). Gene expression of circulating tumour cells in breast cancer patients. European Journal of Medical Research, 14(10), 426-432.
9. Danila, D., Anand, A., Sung, C. C., Heller, G., Leversha, M. A., Cao, L., Lija, H., Molina, A., Sawyers, C. L., Fleisher, M., & Scher, H. I. (2011). TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration resistant prostate cancer. European Urology, 60(5), 897-904.
10. Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir Bauer, S. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R36.
11. Danila, D., Fleisher, M., & Scher, H. I. (2011). Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research, 17(12), 3903-3912.
12. Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diedrichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., & Haber, D. A. (2008). Detection of mutations in EGFR in circulating lung cancer cells. NEJM, 359, 366-377.
13. Leversha, M., Han, J., Asgari, Z., Danila, D. C., Lin, O., Gonzalez-Espinoza, R., Anand, A., Lija, H., Heller, G., Fleisher, M., & Scher, H. I. (2009). Fuorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical Cancer Research, 15, 2091.
14. Swennenjuis, J., Tibbe, A. G., Levink, R., Sipkema, R. C., & Terstappen, L. W. (2009). Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry, 75A(6), 520-527.
15. Cohen, S., Punt, C. K., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W., & Meropol, N. J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(19), 3213-3221.
16. de Bono, J., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W., Pienta, K. J., & Raghavan, D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14, 6302.
17. Cristofanilli, M., et al. (2004). Criculating tumor cells, disease progression and surivival in metastatic breast cancer. NEJM, 351, 781-791.
18. Olmos, D., Baird, R. D., Yap, T. A., Massard, C., Pope, L., Sandhu, S. K., Attard, G., Dukes, J., Papadatos-Pastos, D., Grainger, P., Kaye, S. B., & de Bono, J. S. (2011). Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clinical Cancer Research, 17(15), 5188-5196.
19. Goodman, O., Symanowski, J. T., Loudyi, A., Fink, L. M., Ward, D. C., & Vogelzang, N. J. (2011). Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clinical Genitourinary Cancer, 9(1), 31-38.
20. Danila, D., Heller, G., Cignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lija, H., Schwartz, L., Larson, S., Fleisher, M., & Scher, H. I. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13(23), 7053-7058.
21. Allan, A., & Keeney, M. (2010). Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol. doi: 10.1155/2010/426218.
22. Lowes, L., Lock, M., Rodrigues, G., D'Souza, D., Bauman, G., Ahmad, B., Venkatesan, V., Allan, A. L., & Sexton, T. (2012). Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clinical and Translational Oncology, 14(2), 150-156.
23. Allard, W., Matera, J., Miller, M. C., Repollet, M., Connely, M. C., Rao, C., Tibbe, A. G., Uhr, J. W., & Terstappen, L. W. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patiens with nonmalignant diseases. Clinical Cancer Research, 10(20), 6897-6904.
24. Morgan, T., Lange, P. H., Porter, M. P., Lin, D. W., Ellis, W. J., Gallaher, I. S., & Vessella, R. L. (2009). Disseminated tumor cells in prostate cancer patients after radical prostatectomy without evidence of disease predicts biochemical recurrence. Clinical Cancer Research, 15, 677-683.
25. Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., Kim, J. K., Patel, L. R., Ying, C., Ziegler, A. M., Pienta, M. J., Song, J., Wang, J., Lodberg, R. D., Kresbach, P. H., Pienta, K. J., & Taichman, R. S. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298-1312.
26. Soderberg, S., Karlsson, G., & Karlsson, S. (2009). Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Annals of the New York Academy of Sciences, 1178, 55069.
27. Kiskowski, M., Jackson, R. S., Banerjee, J., Li, X., Kang, M., Iturregui, J. M., Franco, O. E., Hayward, S. W., & Bhowmick, N. A. (2011). Role for stromal heterogeneity in prostate tumorigenesis. Cancer Research, 71(10), 3459-3470.
28. Holcomb, I., Grove, D. I., Kinnunen, M., Friedman, C. L., Gallaher, I. S., Morgan, T. M., Sather, C. L., Delrow, J. J., Nelson, P. S., Lange, P. H., Ellis, W. J., True, L. D., Young, J. M., Hsu, L., Trask, B. J., & Vessella, R. L. (2008). Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Research, 68(14), 5599-5608.
29. Lowe, S., Cepero, E., & Evan, G. (2004). Intrinsic tumor suppression. Nature, 432, 307-315.
30. Pelengaris, S., Khan, M., & Evan, G. I. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Muc and triggers carcinogenic progression. Cell, 109, 321-334.
31. Wu, C., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. PNAS, 103(32), 13028-13033.
32. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
33. Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell, 120, 513-522.
34. Dimri, G., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995). A biomarker that identifies senescent human cells in culture and aging skin in vivo. PNAS, 92, 9363-9367.
35. Udagawa, T. (2008). Tumor dormancy of primary and secondary cancers. APMIS, 116(7-8), 615-628.
36. Marsden, C., Wright, M. J., Carrier, L., Moroz, K., Pochampally, R., & Rowan, B. G. (2012). A novel in vivo model for the study of human breast cancer metastasis using primary pbreast tumor initiating cells from patient biopsies. BMC Cancer, 12(10).
37. Joensuu, K., Leidenius, M. H., Andersson, L. C., & Heikkila, P. S. (2009). High expression of maspin is associated with early tumor relapse in breast cancer. Human Pathology, 40(8), 1143-1151.
38. Hippert, M., O'Toole, P. S., & Thorburn, A. (2006). Autophagy in cancer: good, bad or both? Cancer Research, 66, 9349.
39. Chaterjee, M., & van Golen, K. L. (2011). Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res. doi: 10.1155/2011/362938.
40. Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu, Y., Mills, G. B., Liao, W. S., & Bast, R. C. (2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation, 118(12), 3917-3929.
41. Young, A., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F., Tavare, S., Arakawa, S., Shimizu, S., Watt, F. M., & Narita, M. (2009). Autophagy mediates the mitotic senescence transition. Genes & Development, 23(7), 798-803.
42. Balz, L., Bartkowiak, K., Andreas, A., Pantel, K., Niggemann, B., Zanker, K. S., Brandt, B. H., & Dittmar, Y. (2012). The interplay of Her2/Her3/PI3K and EGFR/Her2/PLC-g1 signalling in breast cancer cell migration and dissemination. J Pathology, 227(2), 234-244.
43. Koebel, C., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450, 903-907.
44. Quesnel, B. (2008). Tumor dormancy and immunoescape. APMIS, 116(7-8), 685-694.
45. Uhr, J. A. M. R. (2001). Dormancy in a model of murine B cell lymphoma. Cancer Biol, 11, 277-283.
46. Naumov, G., Bender, E., Zurakowski, D., Kang, S. Y., Sampson, D., Flynn, E., Watnick, R. S., Straume, O., Akslen, L. A., Folkman, J., & Almog, N. (2006). A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute, 98(5), 316-325.
47. Almog, N., Ma, L., Raychowdhury, R., Schwater, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., & Abdollahi, A. (2009). Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Research, 69(3), 836-844.
48. Park, Y., Kitahara, T., Takagi, R., & Kato, R. (2011). Does surgery for breast cancer induce angiogenesis and thus promote metastasis? Oncology, 81(3-4), 199-205.
49. Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D. R., Butterfield, C. E., Barnes, C. M., Mammoto, A., Mammoto, T., Luria, A., Benny, O., Chaponis, D. M., Dudley, A. C., Greene, E. R., Vergilio, J. A., Pietramaggiori, G., Scherer-Pietramaggiori, S. S., Short, S. M., Seth, M., Lih, F. B., Tomer, K. B., Ynag, J., Schendener, R. A., Hammock, B. D., Falck, J. R., Manthati, V. L., Ingber, D. E., Kaipainen, A., D'Amore, P. A., Kieran, M. W., & Zeldin, D. C. (2012). Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. The Journal of Clinical Investigation, 122(1), 178-191.
50. Indraccolo, S., Minuzzo, S., Masiero, M., Pusceddu, I., Persano, L., Moserle, L., Reboldi, A., Favaro, E., Mecarozzi, M., Di Mario, G., Screpanti, I., Ponzoni, M., Doglioni, C., & Amadori, A. (2009). Cross-talk between tumor and endothelial cells involving the Notch3-DII4 interaction marks escape from tumor dormancy. Cancer Research, 69, 1314.
51. Yefenof, E., Picker, L. J., Scheuermann, R. H., Tucker, T. F., Vitetta, E. S., & Uhr, J. W. (1993). Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proc Nat Acad Sci, 90, 1829-1833.
52. Joensuu, K., Hagstrom, J., Leidenius, M., Haglund, C., Andersson, L. C., Sariola, H., & Heikkila, P. (2011). Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases - elevated Bmi-1 expression in late breast cancer relapses. Virchows Archiv, 459(1), 31-39.
53. Bambang, I., Lu, D., Li, H., Chiu, L. L., Lau, Q. C., Koay, E., & Zhang, D. (2009). Cytokeratin 19 regulates endoplasmic reticulum stress and ihibits ERp29 expression via p38 MAPK/XBP-1 signaling in breast cancer cells. Experimental Cell Research, 315(11), 1964-1974.
54. Allgayer, H., & Aguirre-Ghiso, J. A. (2008). The urokinase receptor (u-PAR) - a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS, 116, 602-614.
55. Yu, W., Kim, J., & Ossowski, L. (1997). Reduction in surface urokinase receptor forces malginant cells into a protracted state of dormancy. The Journal of Cell Biology, 137, 767-777.
56. Aguirre-Ghiso, J., Kovalski, K., & Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signalling. The Journal of Cell Biology, 147, 89-104.
57. Aguirre-Ghiso, J., Liu, D., Mignatti, A., Kovalski, K., & Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Molecular Biology of the Cell, 12, 863-879.
58. Aguirre-Ghiso, J., Estrada, Y., Liu, D., & Ossowski, L. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Research, 63, 1684-1695.
59. Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., Liu, Z. Y., Costes, S. V., Cho, E. H., Lockett, S., Khanna, C., Chambers, A. F., & Green, J. E. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research, 68, 6241-6250.
60. White, D., Kirpios, N. A., Zuo, D., Hassel, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essentail role in mammary tumor induction. Cancer Cell, 2, 159-170.
61. Zhao, J., Reiske, H., & Guan, J. L. (1998). Regulation of the cell cycle by focal adhesion kinase. The Journal of Cell Biology, 143, 1997-2008.
62. Kren, A., Baeriswyl, V., Lehembre, F., Wunderlin, C., Strittmatter, K., Antoniadis, H., Fassler, R., Cavallaro, U., & Christofori, G. (2007). Incrased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO, 26(12), 2832-2842.
63. Lim, P., Bliss, S. A., Patel, S. A., Taborga, M., Dave, M. A., Gregory, L. A., Greco, S. J., Bryan, M., Patel, P. S., & Rameshwar, P. (2011). Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiesence in breast cancer cells. Cancer Research, 71(5), 1550-1560.
64. Kinoshita, Y., Kalier, T., Rahaman, J., Dottino, P., & Kohtz, D. S. (2012). Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. American Journal of Pathology, 180(1), 375-389.
65. Holleb, A., & Folkman, J. (1972). Tumor angiogenesis. CA: A Cancer Journal for Clinicians, 22(4), 226-229.
66. Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging Œ ± 4Œ ≤ 1-positive osteoclast progenitors. Cancer Cell, 20(6), 701-714. doi: 10.1016/j.ccr.2011.11.002.
67. Morrissey, C., Roudier, M. P., Dowell, A., True, L. D., Ketchanji, M., Welty, C., et al. (2012). Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series. Journal of Bone and Mineral Research. doi: 10.1002/jbmr.1749.
68. Martin, T. J., & Sims, N. A. (2005). Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in Molecular Medicine, 11(2), 76-81.
69. McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., et al. (2008). Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 133(6), 994-1005. doi: 10.1016/j.cell.2008.04.045.
70. Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. [10.1038/nm.2890]. Nat Med, 18(9), 1359-1368. http://www.nature.com/nm/journal/v18/n9/abs/nm.2890. html#supplementary-information.
71. Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., Chen, L., Ewing, C. M., Eisenberger, M. A., Carducci, M. A., Nelson, W. G., Yegnasubramanian, S., Luo, J., Wang, Y., Xu, J., Isaacs, W. B., Visakorpi, T., & Bova, G. S. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 15(5), 559-565.
72. Pienta, K., Abate-Shen, C., Agus, D. B., Attar, R. M., Chung, L. W., Greenberg, N. M., Hahn, W. C., Isaacs, J. T., Navone, N. M., Peehl, D. M., Simons, J. W., Solit, D. B., Soule, H. R., VanDyke, T. A., Weber, M. J., Wu, L., & Vessella, R. L. (2008). The current state of preclinical prostate cancer animal models. Prostate, 68(6), 629-639.